Novartis

OXFORD, 17-12-2015 — /EuropaWire/ — Helena Bragd tillsätts som vd för Becton, Dickinson and Companys (BD) affärsenhet BD Nordics. Helena har över 20 års erfarenhet som chef inom farmaceutisk och medicinteknisk verksamhet hos välkända aktörer inom branschen, bland annat ResMed, … Read the full press release →

OXFORD, 17-12-2015 — /EuropaWire/ — Helena Bragd has joined global medical technology leader Becton, Dickinson and Company (BD) as General Manager for the Nordic region. Helena brings more than 20 years of pharmaceutical- and med-tech leadership experience to the role, … Read the full press release →

Ultibro® Breezhaler® met primary endpoint and demonstrated superiority to Seretide® in reducing COPD exacerbations during 52 weeks of treatment First large-scale study to confirm Ultibro Breezhaler is an effective steroid-free option that both reduces exacerbations and improves lung function in … Read the full press release →

Sandoz continues to advance its biosimilars program: Regulatory submission for Sandoz’ proposed biosimilar pegfilgrastim accepted by the FDA Sandoz demonstrates commitment to oncology by seeking approval for its proposed biosimilar pegfilgrastim. Sandoz believes that the totality of evidence in its … Read the full press release →

Phase III data showed median overall survival of 25.6 months in patients with BRAF+ V600E/K metastatic melanoma who received Tafinlar + Mekinist Tafinlar + Mekinist combination also demonstrated significant improvement in health-related quality of life vs vemurafenib monotherapy in this … Read the full press release →

In pivotal study, everolimus reduced risk of disease progression by 52%; showed 11.0-month median progression-free survival vs 3.9 months for placebo[1] Advanced, progressive, nonfunctional neuroendocrine tumors of GI or lung origin are rare forms of cancer with poor prognoses and … Read the full press release →

BASEL, 25-9-2015 — /EuropaWire/ — Pioneering healthcare models that have a transformational impact on the health of the poorest populations in the world lies at the core of the Novartis Foundation. As world leaders meet in New York to discuss … Read the full press release →

Novartis strengthens multiple sclerosis focus with the addition of Ofatumumab to leading MS portfolio which includes Gilenya and investigational treatments BAF312 and CJM112 Ofatumumab is a fully human monoclonal antibody for relapsing remitting multiple sclerosis (RRMS) which targets CD20 and … Read the full press release →

New research from the University of East Anglia could one day help build computers from DNA. NORFOLK, UK, 20-8-2015 — /EuropaWire/ — Scientists have found a way to ‘switch’ the structure of DNA using copper salts and EDTA (Ethylenediaminetetraacetic acid) … Read the full press release →

Princeton, New Jersey, 30-7-2015 — /EuropaWire/ — Sandoz today announced the US market introduction of its budesonide inhalation suspension, a generic version of Pulmicort Respules® (budesonide) inhalation suspension 1 mg strength by AstraZeneca LP. Sandoz’s budesonide inhalation suspension product is indicated … Read the full press release →

Non-communicable diseases like asthma are rising rapidly in sub-Saharan Africa where healthcare systems are ill-prepared to cope1 – Zambia is ranked #1 in the world for mortality due to asthma2 Increasing the medical expertise of local healthcare professionals is a … Read the full press release →

GlaxoSmithKline plc (LSE/NYSE: GSK) today announced it is divesting its meningitis vaccines Nimenrix and Mencevax to Pfizer Ireland Pharmaceuticals (a subsidiary of Pfizer Inc). LONDON, 24-6-2015 — /EuropaWire/ — The sale follows commitments given to the European Commission and other … Read the full press release →

Patients on Tasigna achieved rapid and high rates of molecular response with a very low rate of progression to advanced disease ENEST1st data confirm the favorable benefit/risk profile of Tasigna in newly-diagnosed CML patients seen in the pivotal ENESTnd study … Read the full press release →

Panobinostat combination more than doubled median PFS benefit by 7.8 months in patients who received >=2 prior lines of therapy, including bortezomib and IMiD[1] Multiple myeloma is an incurable cancer of the plasma cells, a type of white blood cell … Read the full press release →

Arzerra significantly improved PFS when added to fludarabine + cyclophosphamide (median 28.9 mos vs 18.8 mos) after initial treatment stopped working Patients receiving Arzerra plus existing CLL treatments also had a higher overall response rate (84% vs 68%) compared to … Read the full press release →

New analysis from pivotal Phase III studies show Xolair® (omalizumab) significantly improved quality of life scores for Chronic Spontaneous Urticaria (CSU) patients compared to placebo[1],[2] Additional data at WCD show the consistent negative health impact and economic burden of CSU, … Read the full press release →

Promacta® (eltrombopag) significantly increased and sustained platelet counts in two studies, including the largest Phase III clinical trial in this patient population Characterized by a low platelet count[1], ITP can affect up to 5 in 100,000 children each year[2] and … Read the full press release →

Cosentyx (secukinumab) met the primary endpoints of superiority compared to placebo in patients with difficult-to-treat psoriasis of the nails, palms and soles[1],[2] One third of patients with moderate-to-severe palmoplantar psoriasis achieved clear or almost clear skin on their palms and … Read the full press release →

LONDON, 2-6-2015 — /EuropaWire/ — AstraZeneca and MedImmune, the company’s global biologics research and development arm, today presented encouraging results from their novel combination-focused immuno-oncology portfolio at the American Society of Clinical Oncology (ASCO) Annual Meeting 2015. Overall, data indicated … Read the full press release →

Study in patients with advanced nonfunctional neuroendocrine tumors (NET) of gastrointestinal (GI) or lung origin met primary endpoint[1] Full results will be submitted for presentation at a major medical meeting; worldwide regulatory filings are planned for 2015 Afinitor is already … Read the full press release →